JPRN-UMIN000002900已完成1 期
A Phase I/II study of Pemetrexed plus Erlotinib therapy in Previously Treated Non-Small-Cell Lung Cancer. - A Phase I/II study of Pemetrexed plus Erlotinib therapy in Previously Treated Non-Small-Cell Lung Cancer.
Osaka Univ.Hospital Respiratory Medicine0 个研究点目标入组 40 人开始时间: 2009年12月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with idiopathic pulmonary fibrosis, other interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug induced pulmonary damage 2) Patients with pleural effusion, ascites and/or pericardial effusion requiring drainage 3) Patients with infection requiring iv administration of antibiotics and/or antifungal agents 4) Patients unable to be treated with PO drugs 5) Clinically significant eye diseases such as severe dry eye, keratoconjunctivitis 6) Pregnancy, breast feeding and suspected pregnancy 7) Severe bone marrow suppression 8) Symptomatic brain metastasis 9) Active synchronous malignancies 10) Severe renal function disorder (creatinin clearlance less than 45mL/min) 11) Uncontrolled diabetes mellitus 12) Other clinically significant complications 13) Other conditions inadequate for this research
研究者
相似试验
招募中
2 期
A phase II study of Erlotinib plus Pemetrexed for Non Small Cell Lung Cancer with T790M negative previously treated with EGFR-TKIon-small cell lung cancerJPRN-UMIN000008033Toho University Omori Medical Center15
已完成
2 期
A phase II study of Erlotinib plus Pemetrexed for previously treated Non Small Cell Lung Canceron-Small Cell Lung CancerJPRN-UMIN000007397Kochi University, School of Medicine, Department of Hematology and Resporatory Medicine27
进行中（未招募）
不适用
Pemetrexed in combination with erlotinib as a salvage treatment in patients with metastatic biliary tract cancer (BTC) who failed gemcitabineNeoplasmsKCT0005787Samsung Medical Center44
招募中
1 期
A phaseI/II study of Erlotinib/Carboplatin/Pemetrexed/Bevacizumab in chemotherapy-naive patients with EGFR mutation positive advanced non-squamous non-small-cell lung canceron-Small-Cell Lung CancerJPRN-UMIN000013202Kansai Medical University Hirakata Hospital35
进行中（未招募）
1 期
A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed alone, and Erlotinib alone, as Second-Line Treatment for Non-Smoker Patients with Locally Advanced or Metastatic Non-Small Cell Lung CancerEUCTR2007-003912-72-GBEli Lilly and Company Limited237